Jacobio Pharma's Clinical Trial Application for BET Inhibitor JAB-8263 Approved for Autoimmune Diseases Jacobio Pharma has received approval for their Phase I/II clinical trial application for the BET inhibitor JAB-8263 aimed at treating autoimmune diseases.

Jacobio Pharma's Clinical Trial Application for BET Inhibitor JAB-8263 Approved for Autoimmune Diseases #China #Beijing #Jacobio_Pharma #BET_Inhibitor #JAB-8263

Jacobio Pharma Unveils Promising BET Inhibitor Data for Treating Myelofibrosis at 2024 ASH Annual Meeting Jacobio Pharma has presented promising preliminary data on its BET inhibitor, JAB-8263, for myelofibrosis treatment at the 2024 ASH Annual Meeting.

Jacobio Pharma Unveils Promising BET Inhibitor Data for Treating Myelofibrosis at 2024 ASH Annual Meeting #China #Beijing #Myelofibrosis #Jacobio_Pharma #BET_Inhibitor